Abstract 2203P
Background
Malignant pleural mesothelioma (MPM) is a rare and aggressive disease with poor prognosis. MPM is classified into three histological subtypes: epithelioid, biphasic, and sarcomatoid. This classification does not account for survival differences and intratumor heterogenity, especially for epithelioid MPM (eMPM) that is the most common subtype. The aim of this study is to evaluate transcriptomic differences of eMPM based on prognostic classes.
Methods
MPM patients with available FFPE tissue were retrospectively and prospectively enrolled at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan and Azianda Sanitaria Universitaria Giuliano Isontina of Trieste between 2006 and 2021 within the granted Italian MOH project, GR-2016-02361229. RNA was automatically extracted and quantified using a fluorometer. Transcriptome was assessed through the 3’DGE method. Patients were divided into three groups based on months (mo) of survival: long survivors (LS) > 36 mo, normal survivors (NS) > 12 and ≤ 36 m, and short survivors (SS) ≤ 12 mo. Evaluation of differential gene expression (GED) between SS and LS was performed for single genes. Moreover, in the same setting, a gene set enrichment analysis (GSEA) was also performed.
Results
125 eMPM cases were enrolled, 90 (72%) males and 35 (28%) females, with a median age at diagnosis of 72 years. At a median follow-up of 88 mo, the median overall survival (OS) was 21 mo. Among patients, 33 were LS, 54 were NS, and 38 were SS. GED showed higher levels of NUF2 and TUBB3, genes involved in the epithelial-mesenchimal-transition (EMT), and a lower expression of ADH1B, PLA2G2A, genes related to metabolism, in SS. EMT, metabolism signature and cell proliferation were confirmed by GSEA analysis as more positively correlated pathways while inflammation and immune response related pathways were negatively correlated in SS.
Conclusions
Transcriptomic characterization of eMPM reinforces the hypothesis that cell cycle, EMT and immune components could have an impact on eMPM outcome and could be exploited as therapeutic strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Italian Ministry of Health.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07